GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
CSPC will receive an upfront payment of $100 million from AstraZeneca
GSK and Flagship to jointly fund up to $150 million upfront
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Subscribe To Our Newsletter & Stay Updated
